Bruker Corporation (BRKR) Acquires Biocrates to Expand Multiomics Solutions

Bruker Corporation (NASDAQ:BRKR) announced the acquisition of Biocrates Life Sciences AG, a prominent Austrian company specialized in quantitative metabolomics. While the financial details remain undisclosed, the transaction is anticipated to integrate advanced multiomics technologies into the company’s expanding life sciences portfolio.

Bruker Corporation (BRKR) Acquires Biocrates to Expand Multiomics Solutions

A scientist in a laboratory wearing safety gear while operating a mass spectrometry machine.

Bruker Corporation (NASDAQ:BRKR) has intensified its focus on omics in recent years. Having previously acquired proteomics-focused companies PreOmics and Biognosys, the company’s presence in the field is strengthened further with its latest addition of Biocrates, which introduces standardized metabolite and lipid analysis kits covering over 1,000 metabolites across more than 40 classes.

The acquisition will complement the company’s mass spectrometry (MS)-based platforms, as well as supporting a unified approach across proteomics and metabolomics operations. Dr. Oliver Rinner, Bruker Corporation (NASDAQ:BRKR)’s Vice President for Enabling Multiomics Solutions and founder and CEO of Biognosys, made the following comment:

“…biocrates adds key metabolomics solutions to the Bruker portfolio. With our services, software and kits for high-end proteomics and metabolomics we can now support customers with a truly integrated multiomics approach.”

Analyst sentiment remains mixed. On May 22, 2025, Citi downgraded the stock from Buy to Neutral, slashing the price target from $50 to $40, citing exposure to volatility in U.S. Academic and Government demand. Meanwhile, after the announcement today, Bank of America Securities stands by its Buy rating with a price target of $61.00.

Massachusetts-based company, Bruker Corporation (NASDAQ:BRKR), develops and manufactures scientific instruments for molecular and materials research, as well as for industrial and applied analysis. The company’s core focus is directed towards spans life sciences, diagnostics, and analytical chemistry.

While we acknowledge the potential of BRKR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BRKR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds

Disclosure: None.